Translational Knowledge Discovery Between Drug Interactions and Pharmacogenetics

Clinical translation of drug‐drug interaction (DDI) studies is limited, and knowledge gaps across different types of DDI evidence make it difficult to consolidate and link them to clinical consequences. Consequently, we developed information retrieval (IR) models to retrieve DDI and drug‐gene interaction (DGI) evidence from 25 million PubMed abstracts and distinguish DDI evidence into in vitro pharmacokinetic (PK), clinical PK, and clinical pharmacodynamic (PD) studies for US Food and Drug Administration (FDA) approved and withdrawn drugs. Additionally, information extraction models were developed to extract DDI‐pairs and DGI‐pairs from the IR‐retrieved abstracts. An overlapping analysis identified 986 unique DDI‐pairs between all 3 types of evidence. Another 2,157 and 13,012 DDI‐pairs and 3,173 DGI‐pairs were identified from known clinical PK/PD DDI, clinical PD DDI, and DGI evidence, respectively. By integrating DDI and DGI evidence, we discovered 119 and 18 new pharmacogenetic hypotheses associated with CYP3A and CYP2D6, respectively. Some of these DGI evidence can also aid us in understanding DDI mechanisms.

[1]  David A. Flockhart,et al.  The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen , 2006, Breast Cancer Research and Treatment.

[2]  M. J. Hall,et al.  National Hospital Discharge Survey: 2007 summary. , 2010, National health statistics reports.

[3]  Juancarlos Chan,et al.  Gene Ontology Consortium: going forward , 2014, Nucleic Acids Res..

[4]  Emily R. Hajjar,et al.  Polypharmacy in elderly patients. , 2007, The American journal of geriatric pharmacotherapy.

[5]  Ira J. Kalet,et al.  Computing with evidence: Part II: An evidential approach to predicting metabolic drug-drug interactions , 2009, J. Biomed. Informatics.

[6]  N. Xu,et al.  CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients , 2014, Pediatric transplantation.

[7]  K. Verbeke,et al.  Tacrolimus Dose Requirements and CYP3A5 Genotype and the Development of Calcineurin Inhibitor-Associated Nephrotoxicity in Renal Allograft Recipients , 2010, Therapeutic drug monitoring.

[8]  Russ B. Altman,et al.  Discovery and Explanation of Drug-Drug Interactions via Text Mining , 2011, Pacific Symposium on Biocomputing.

[9]  Paloma Martínez,et al.  Lessons learnt from the DDIExtraction-2013 Shared Task , 2014, J. Biomed. Informatics.

[10]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[11]  อนิรุธ สืบสิงห์,et al.  Data Mining Practical Machine Learning Tools and Techniques , 2014 .

[12]  C. Obasaju,et al.  Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Isabel Segura-Bedmar,et al.  The 1st DDIExtraction-2011 challenge task: Extraction of Drug-Drug Interactions from biomedical texts , 2011 .

[14]  P. Stratta,et al.  Severe acute nephrotoxicity in a kidney transplant patient despite low tacrolimus levels: a possible interaction between donor and recipient genetic polymorphisms , 2013, Journal of clinical pharmacy and therapeutics.

[15]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[16]  V. Dolžan,et al.  Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma , 2017, Scientific Reports.

[17]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype , 2012, Clinical pharmacology and therapeutics.

[18]  Weilong Shang,et al.  Simvastatin-induced myopathy with concomitant use of cyclosporine: case report. , 2011, International journal of clinical pharmacology and therapeutics.

[19]  S. Hennessy,et al.  The Need for Translational Research on Drug–Drug Interactions , 2012, Clinical pharmacology and therapeutics.

[20]  Donghui Cui,et al.  Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective , 2013, The AAPS Journal.

[21]  David A. Flockhart,et al.  Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[22]  Magnus Ingelman-Sundberg,et al.  The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects , 2010, Human Genomics.

[23]  E. Brown,et al.  The Medical Dictionary for Regulatory Activities (MedDRA) , 1999, Drug safety.

[24]  Xu Han,et al.  An integrated pharmacokinetics ontology and corpus for text mining , 2013, BMC Bioinformatics.

[25]  H. Mano,et al.  Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro. , 2006, Oncology research.

[26]  L. Wang,et al.  Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study. , 2015, Genetics and molecular research : GMR.

[27]  Xu Han,et al.  Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions , 2012, PLoS Comput. Biol..

[28]  Russ B. Altman,et al.  Learning the Structure of Biomedical Relationships from Unstructured Text , 2015, PLoS Comput. Biol..

[29]  L Gong,et al.  The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy , 2012, Clinical pharmacology and therapeutics.

[30]  Ira J. Kalet,et al.  Computing with evidence: Part I: A drug-mechanism evidence taxonomy oriented toward confidence assignment , 2009, J. Biomed. Informatics.

[31]  H. McLeod,et al.  Tamoxifen and CYP2D6: a contradiction of data. , 2012, The oncologist.

[32]  R. Niska,et al.  National Hospital Ambulatory Medical Care Survey: 2007 emergency department summary. , 2010, National health statistics reports.

[33]  César de Pablo-Sánchez,et al.  Using a shallow linguistic kernel for drug-drug interaction extraction , 2011, J. Biomed. Informatics.

[34]  Chitta Baral,et al.  Discovering drug–drug interactions: a text-mining and reasoning approach based on properties of drug metabolism , 2010, Bioinform..

[35]  Paloma Martínez,et al.  A linguistic rule-based approach to extract drug-drug interactions from pharmacological documents , 2011, BMC Bioinformatics.